SCHEMBL5048072

SCHEMBL5048072

C#Cc1ccc(C(=O)N(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
HPGD P15428 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ACACB O00763 1/20 0.44
NEK2 P51955 1/20 0.41
ERN1 O75460 1/20 0.40
MAOB P27338 1/20 0.40
AOC3 Q16853 1/20 0.40
HSP90AA1 P07900 1/20 0.39
PDK2 Q15119 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
MAPT P10636 1/20 0.38
F10 P00742 1/20 0.38
EGLN1 Q9GZT9 1/20 0.37
PIK3CA P42336 1/20 0.37
MTOR P42345 1/20 0.37
NCOA1 Q15788 1/20 0.37
NCOA3 Q9Y6Q9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3422014 0.84 ALDH1A1 (0.37) ALDH1A1HPGDSMN1; SMN2ACACBMAPT
SCHEMBL1004649 0.82 ALDH1A1 (0.73) ALDH1A1HPGDSMN1; SMN2ERN1MAOB
SCHEMBL6320976 0.81 ALDH1A1 (0.55) ALDH1A1HPGDSMN1; SMN2ACACBERN1
SCHEMBL123989 0.80 NSD2 (0.42) ALDH1A1HPGDSMN1; SMN2ACACB
SCHEMBL10933810 0.79 NSD2 (0.55) ALDH1A1HPGDSMN1; SMN2ACACBPDK2
SCHEMBL3610292 0.79 HPGD (0.56) ALDH1A1HPGDSMN1; SMN2HSP90AA1MAPT
SCHEMBL8160105 0.78 HDAC4 (0.45) ACACBMAOBPDK2
SCHEMBL13891405 0.78 ALDH1A1 (0.52) ALDH1A1HPGDSMN1; SMN2ACACBERN1
SCHEMBL21115241 0.77 NSD2 (0.43) ALDH1A1ACACBMAOBAOC3
SCHEMBL15801078 0.77 DRD2 (0.40) ACACBMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10889546-B2 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2021-01-12 US disclosed
US-20200407319-A1 ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. 2020-12-31 US disclosed
CN-107848976-B Alkynyl pyridine prolyl hydroxylase inhibitor, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2020-11-17 CN disclosed
EP-3360862-B1 ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO (CN) 2020-04-22 EP disclosed
US-20180305317-A1 ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2018-10-25 US disclosed
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US disclosed
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP disclosed
EP-1682528-A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP disclosed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US disclosed
WO-2005044814-A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-05-19 WO disclosed
EP-0114632-B1 5-(4-VINYL- OR 4-ETHYNYLBENZOYL)-1,2-DIHYDRO-3H-PYRROLO-(1,2-A)-PYRROLE-1-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF SYNTEX (U.S.A.) INC. (US) 1987-09-16 EP disclosed
US-4560699-A ANTIPYRETICS, ANTICOAGULANTS, VASODILAAORS, MUSCLE RELAXANTS SYNTEX (U.S.A.) INC. (US) 1985-12-24 US disclosed
EP-0114632-A1 5-(4-Vinyl- or 4-ethynylbenzoyl)-1,2-dihydro-3H-pyrrolo-(1,2-A)-pyrrole-1-carboxylic acids and derivatives thereof SYNTEX (U.S.A.) INC. (US) 1984-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180305317-A1 ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF EGLN3, EGLN2, EPOR ALDH1A1 54/4885HPGD 247/4885SMN1; SMN2 2171/4885
US-10889546-B2 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof EGLN3, EGLN2, EPOR ALDH1A1 54/4885HPGD 247/4885SMN1; SMN2 2171/4885
US-20200407319-A1 ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF EGLN3, EGLN2, EPOR ALDH1A1 54/4885HPGD 247/4885SMN1; SMN2 2171/4885
US-20050113374-A1 Benzodioxepine derivatives BBOX1, ACOX1, ACOX3 ALDH1A1 361/4885HPGD 260/4885SMN1; SMN2 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.